<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669562</url>
  </required_header>
  <id_info>
    <org_study_id>QLDE201801/PRO</org_study_id>
    <nct_id>NCT03669562</nct_id>
  </id_info>
  <brief_title>The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers</brief_title>
  <official_title>The Safety, Tolerability and Pharmacokinetic Phrase I Study of Alprostadil Fat Emulsiom Injection in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conducted in Chinese healthy adult volunteers,the study aims to observe the safety,
      tolerability and pharmacokinetic of single-dose administration of different doses of
      Alprostadil Liposome for Injection as well as to confirm the safety dose range.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>8 days</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Lower Extremity Arterial Occlusive Diseases</condition>
  <arm_group>
    <arm_group_label>Alprostadil liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprostadil Liposome for Injection</intervention_name>
    <description>intravenous infusion Alprostadil Liposome</description>
    <arm_group_label>Alprostadil liposome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion liposome control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers are at least 18 years of age and no older than 40.

          -  BMI are at least 19.0kg/m2,and no more than 24.0kg/m2.(The male weight is greater than
             or equal to 50kg.The female weight is greater than or equal to 50kg.)Subjects who are
             overweight or underweight will not be inclusion.

          -  Subjects with normal medical history,vital signs,physical examination and clinical
             examination (routine blood,routine urine,blood chemistry,coagulation function and
             ECG,X-ray,intraocular pressure and so on).

          -  A negative hepatitis B surface antigen,hepatitis C,HIV or syphilis test result.

          -  Subjects with the ability to communicate with investigators.Besides,subjects must be
             willing to remain at the study center as required per protocal to complete all visit
             assessments.

        Exclusion Criteria:

          -  Subjects have brain dysfunction,mental development disorders or speech disorders that
             unable to communicate with investigators.

          -  Subjects with a history of psychiatric disease or drug dependence.

          -  Subjects with a medical history about cardiac,liver,renal,digestive system or
             neurological.

          -  Subjects with the family history of diabetes,the history of
             pancreatitis,cholelithiasis or asthma.

          -  Subjects significantly abuse alcohol or tobacco.

          -  Drink in 24 hours before post-dosing of study drug.

          -  Subjects who had taken medications within 2 weeks.

          -  Subjects who had suffer from exsanguine or donated blood over 400ml within 3 months
             will be excluded.

          -  Subjects who participate in other clinical trials within 3 months will be excluded.

          -  History of hypersensitivity or allergy to any of the study drugs or to drugs of
             similar chemical classes.

          -  Subjects with a history of fainting.

          -  Subjects who had infected for unknown reason.

          -  Subjects with interstitial pneumonia.

          -  Subjects with glaucoma or intraocular pressure with hyperthyroidism.

          -  Women who are pregnant or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peng Yue Ying, Master</last_name>
    <phone>15931108221</phone>
    <email>pengyueying@mail.ecspc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xuhuiqu central hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Chen, bachelor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>September 11, 2018</last_update_submitted>
  <last_update_submitted_qc>September 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

